Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
TransMedics Group, Inc. is a medical technology company focused on improving outcomes in organ transplantation by enabling the preservation, assessment, and transportation of donor organs outside the human body. The company operates within the medical devices and healthcare services industries, with a primary emphasis on advanced organ perfusion systems that allow donor organs to remain metabolically active during transport. Its core mission is to increase the utilization of donor organs and expand access to life-saving transplants.
The company’s primary revenue drivers are its Organ Care System (OCS) platforms for heart, lung, and liver transplantation, along with related disposable components and clinical services. TransMedics serves transplant centers, organ procurement organizations (OPOs), and healthcare systems, primarily in the United States and select international markets. Founded in 1998, the company evolved from a device-focused innovator into a vertically integrated transplant logistics and services provider, particularly following the commercialization of its National OCS Program.
Business Operations
TransMedics generates revenue through the sale and utilization of its OCS Heart System, OCS Lung System, and OCS Liver System, which combine proprietary hardware, software, and single-use disposables. A significant portion of revenue is derived from its National OCS Program (NOP), a turnkey service model that integrates organ retrieval, preservation, monitoring, and transportation using TransMedics-owned assets and clinical teams. This service-based model represents a strategic shift toward recurring and per-procedure revenue.
Operations are primarily based in the United States, with additional commercial activity in Europe and other international markets. The company controls proprietary perfusion technologies, digital monitoring systems, and a logistics infrastructure that includes dedicated aircraft and clinical specialists. TransMedics conducts its commercial, manufacturing, and clinical operations through wholly owned subsidiaries, and no material joint ventures have been publicly disclosed as of the most recent filings.
Strategic Position & Investments
TransMedics’ strategy centers on expanding the adoption of normothermic machine perfusion as a standard of care in organ transplantation. Growth initiatives include increasing penetration of the National OCS Program, expanding indications for existing OCS platforms, and pursuing regulatory approvals for additional organ types and geographies. The company has invested heavily in clinical trials, logistics capabilities, and internal infrastructure to support end-to-end transplant services.
Notable strategic investments include the acquisition of Bridge to Life Ltd., which enhanced TransMedics’ portfolio of organ preservation solutions and strengthened its supply chain. The company is also involved in emerging areas such as advanced data analytics for organ assessment and expanded-criteria donor utilization. These initiatives position TransMedics as both a technology provider and a comprehensive transplant services company.
Geographic Footprint
TransMedics is headquartered in Andover, Massachusetts, and its primary commercial operations are concentrated in the United States, which represents the majority of revenue. The company maintains a growing presence in Europe, including countries where OCS systems have received regulatory clearance and are used by leading transplant centers.
Internationally, TransMedics’ influence is expanding through direct sales, distributor relationships, and clinical collaborations. While North America remains the core market, the company continues to pursue broader adoption across Europe and selectively in other regions where transplant volumes and regulatory pathways support growth.
Leadership & Governance
TransMedics was founded by Waleed Hassanein, who continues to play a central role in shaping the company’s long-term vision of transforming organ transplantation through technology and integrated services. The leadership team emphasizes clinical evidence generation, operational control, and innovation-driven growth as core elements of its strategic philosophy.
Key executives include:
- Waleed Hassanein – Founder, President, and Chief Executive Officer
- Stephen Gordon – Chief Financial Officer
- Eric Major – Executive Vice President, International
- John Whelan – Executive Vice President, Operations
- Chad Nixon – Senior Vice President, Sales and Marketing
The company operates under a governance structure typical of publicly traded U.S. medical device companies, with oversight by an independent board of directors and compliance with applicable regulatory and reporting standards.